SUMOylation in cancer: molecular mechanisms and therapeutic implications - PubMed
3 hours ago
- #Cancer Immunotherapy
- #Tumor Immune Microenvironment
- #SUMOylation
- SUMOylation is a key post-translational modification with dual roles in cancer, affecting tumor cells and the tumor immune microenvironment (TIME).
- It promotes immune evasion through mechanisms such as suppressing antigen presentation, limiting immunopeptidome diversity, regulating immune checkpoints like PD-L1 and TIGIT, and modulating immune cell differentiation and function.
- Pharmacological inhibitors of SUMOylation (e.g., TAK-981, ML792) reverse immunosuppressive effects by restoring antigen presentation, activating type I interferon responses, enhancing CD8+ T cell cytotoxicity, and reducing regulatory T cells.
- SUMOylation-related gene signatures show potential as prognostic markers and indicators of immunotherapy response, though prospective validation is still needed.
- Preclinical models indicate that SUMOylation inhibitors synergize with immune checkpoint blockade to boost anti-tumor efficacy, but clinical validation is pending.
- This review consolidates knowledge on SUMOylation's molecular mechanisms and therapeutic implications for cancer immunotherapy.